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INTRODUCTION 
Thyroid cancers are one of the common endocrine cancers. There 
is a notable increase in the incidence of thyroid cancers worldwide over 
the past two decades, probably due to the use of more sensitive detection 
techniques and environmental changes. Most thyroid neoplasms are 
primary tumours. Traditionally, they have been classified as adenomas 
and carcinomas. 
Lesions exhibiting follicular cell differentiation comprise more 
than 95% of the total cases. (1) 
Thyroid follicular neoplasms are composed of wide range of 
lesions which includes benign adenomatous nodule, follicular adenoma 
(FA), follicular carcinoma (FC) and follicular variant of papillary 
carcinoma (FVPC). 
 The Diagnosis of follicular carcinoma is based on the presence of 
capsular invasion or vascular invasion or nodal or distant metastasis, 
which is sometimes problematic for pathologists (2) 
For the purpose of easing the diagnosis, different tools such as 
Immunohistochemistry and molecular profiling have been used to 
differentiate between benign and malignant follicular neoplasms. 
2 
 
Prostate Specific Membrane Antigen (PSMA) is a type II integral 
membrane glycoprotein expressed in prostate cancer cells. Later it was 
discovered that it is also expressed in the neovasculature of the various 
other solid tumours. But neither normal endothelium nor endothelial cells 
of benign tissue are positive for PSMA (3).  
This study is conducted to evaluate the expression of PSMA by 
immunohistochemistry in neovasculature of thyroid follicular neoplasms 
and to determine its usefulness in distinguishing between adenoma and 
carcinoma.  
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AIMS AND OBJECTIVES 
 
1. To study the frequency of occurrence of Thyroid Follicular 
neoplasm in specimens received at the Department of pathology, 
Madurai Medical College, Madurai. 
2. To study the age and sex related incidence of thyroid follicular 
neoplasms. 
3. To assess the expression of prostrate specific membrane antigen 
(PSMA) in selected cases of thyroid follicular neoplasms and it’s 
utility in differentiating between benign and malignant lesions. 
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REVIEW OF LITERATURE 
Historical Aspects 
THOMAS WHARTON, an English physician and anatomist from 
London in 1656 named this endocrine gland as thyroid gland as it 
resembled the shield used in ancient Greece. 
Embryology  
The thyroid gland develops as an epithelial proliferation in the 
floor of pharynx between the tuberculum impar and copula at a point 
which is later represented as foramen cecum. After development, the 
thyroid descends in front of the pharyngeal gut as a bilobed diverticulum. 
During the course of this migration the thyroid gland remains 
connected to the tongue by a narrow canal, called the thyroglossal duct 
which disappears later.  
With further development, the thyroid gland descends in front of 
hyoid bone and laryngeal cartilages. By seventh week it reaches its final 
position. 
By this time it acquires a small median isthmus and two lateral 
lobes. Approximately, by the end of third month, thyroid begins to 
function, at which time the first follicles containing colloid becomes 
visible. This development of the thyroid gland is controlled by the 
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coordinated action of specific transcription factors such as TTF-1, TTF-2, 
PAX8, and HHEX, and the altered expression of which likely plays an 
important role in thyroid dysgenesis. (4) 
Anatomy  
The thyroid is the largest of the endocrine glands, weighing 
between 20 and 25 gm. The thyroid gland is located in the neck, just 
below the larynx. It consists of two lobes; each measures about 5 cm, 
connected anteriorly by a bridge of tissue called the isthmus. It receives 
an abundant blood supply of about 80–120 ml/min, through the paired 
superior thyroid artery and the paired inferior thyroid artery which are 
branches of external carotid arteries and subclavian arteries respectively. 
The venous drainage is through the paired superior and middle thyroid 
veins which passes to the internal jugular veins and through the inferior 
thyroid veins that empty into brachiocephalic veins. (5) 
Histology 
Thyroid follicles are the functional units of thyroid glands.They are 
composed of a single layer of cuboidal epithelial cells, with a basement 
membrane, the follicles are of variable sizes and they contain a 
homogeneous colloid. The thyroid gland is enveloped by a fibrous 
capsule, which forms fine collagenous septa extending into the gland and 
dividing it into lobules and also conveys rich blood supply, along with 
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lymphatics and nerves. Tiny capillaries pierce the thyroid tissue and 
surround the follicles. They are usually difficult to see in a Haematoxylin 
& Eosin preparation, but they can be highlighted using an 
immunohistochemical method for an endothelial marker. 
The function of thyroid follicles is mainly to store thyroglobulin 
(an iodinated glycoprotein) the storage form of thyroxine (T4) and tri-
iodothyronine (T3). The follicles epithelial cells are responsible for the 
synthesis of the glycoprotein component of thyroglobulin and for the 
conversion of iodide to iodine. The inactive thyroid epithelial cells are 
flat or cuboidal cells, whereas cells actively synthesising or secreting 
thyroid hormones are tall and columnar. 
C cells 
A second type of cell is the C cell or parafollicular cell that has 
ultrastructural characteristics of neuroendocrine cells. The major 
secretion by the C cell is calcitonin. C cells are relatively difficult to 
identify in haematoxylin-eosin–stained sections, even though they 
sometimes exhibit cytoplasmic clearing. They can be recognized in Diff-
Quick–stained smear because their cytoplasm contains metachromatic 
granules. C cells are most reliably identified by immunehistochemical 
methods by using antibodies to calcitonin or chromogranin A. C cells 
occupy an exclusively intrafollicular position and are separated from the 
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interstitium by the follicular basal lamina and from the colloid by the 
cytoplasm of adjacent follicular cells. C cells are seen in highest 
concentrations in a zone of the junction of the upper and middle thirds of 
the lateral lobes. They are generally present as single cells or as small cell 
clusters. As many as 50 C cells are present per single low-power field 
(×100) in adults.  
A detailed morphometric study, demonstrated a significant inter-
individual variation in the maximum C-cell surface area, which ranged 
from 28 × 103 to 470 × 103 μm2in adults (6). They also demonstrated that 
C-cell density in males was more than twice that of the females, 
paralleling the known higher levels of calcitonin in males.  
The primary transcript of the calcitonin gene gives rise to two 
different mRNAs by tissue-specific alternative splicing events, calcitonin 
and the calcitonin gene–related peptide mRNAs. The calcitonin gene–
related peptide is expressed in thyroid and nervous tissue, but calcitonin 
is being produced in large quantities only in the thyroid gland. In addition 
to calcitonin production, the C cells also produce a variety of other 
peptides that includes somatostatin, gastrin-releasing peptide, and 
thyrotropin - releasing hormone. They also have biologically active 
amines, including serotonin. Ultra structurally, C cells contain 
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membrane-bound secretary granules, which are representative of the sites 
of storage of calcitonin and other peptides. 
Physiology 
Synthesis of thyroid hormone begins by active transport of iodide 
which is the ionized form of iodine, into the follicular cells, which is 
mediated by the sodium-iodide symporter. The intracellular iodide is then 
oxidized by an enzyme called thyroid peroxidase and is bound to tyrosine 
to form the hormonally inactive iodotyrosines, monoiodotyrosine and 
diiodotyrosine. The formation of T4 occurs as results from coupling of 
two diiodotyrosine molecules, as the formation of T3 results from the 
coupling of one molecule of monoiodotyrosine and one molecule of 
diiodotyrosine. 
The iodothyronine molecules are further incorporated into 
thyroglobulin. The stimulation of the follicular cells by thyroid-
stimulating hormone (TSH) results in the resorption of colloid through 
the apical aspect of the follicular cell and the subsequent release of T4 
and T3 at the basal aspect of the cell from where they subsequently enter 
the systemic circulation.  
The iodotyrosines undergoes subsequent intra thyroid iodination, 
with recycling of the resulting free iodide. Thyroid hormone synthesis 
and secretion are controlled by the actions of TSH and thyroid hormone 
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releasing in a classic negative feedback pathway. Thyroid-releasing 
hormone stimulates the synthesis and release of TSH, whereas T3 and T4 
inhibit these activities. The activity of the genes coding for thyroglobulin, 
thyroid peroxidase, the TSH receptor, and sodium-iodide transporter are 
mainly controlled by three thyroid transcription factors, TTF-1, TTF-2, 
and Pax-8. 
Thyroid Nodules and Thyroid Cancers -General Considerations 
The prevalence of thyroid nodules in population depends on many 
factors that include age, geographic location, and the sensitivity of the 
detection system. The prevalence of thyroid  nodules is five to ten times 
higher in glands studied through ultrasonography.Of those nodules which  
have been surgically removed, 42% to 77% proved to be hyperplastic 
nodules, 15% to 40% were adenomas, and 8% to 17% were carcinomas.(7) 
The estimated age standardized annual incidence is 1.0 to 2.9 cases 
per 1000,000 men and 3.4 to 9.1 cases per 100000 women, with higher 
incidence in developed and lower incidence in developing countries (8).In 
the Framingham study conducted, thyroid nodules were identified 
clinically in 6.4% of female population and 1.5% of male population, 
with a nodule   with an accurate rate of 0.09% per annum. (9) 
Approximately 95% of all thyroid cancers are primary carcinomas. 
With less than 5 % of thyroid cancer contributed by Primary lymphomas 
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of the thyroid, majority of them possibly evolved from autoimmune 
(lymphocytic) thyroiditis. 
Sarcomas of the thyroid are very rare. About 20% of patients, who 
died of metastasizing malignancy, had metastatic deposits in the thyroid 
gland, most commonly from renal cell carcinomas, malignant melanoma, 
and bronchogenic carcinoma. 
Epidemiology 
The true incidence of follicular adenomas is generally difficult to 
establish with high accuracy since they cannot be discriminated from 
solitary the hyperplasic nodules based on clinical parameters or FNA. 
The incidence of adenomas in adults can be estimated to about 3% 
to 5% based up on autopsy series (10).Palpable thyroid nodules are found 
in between 3% to 7% of adults who are living in iodine-sufficient areas, 
and three fourths of those are solitary nodules on palpation and might 
represent adenomas (11). Follicular adenomas are frequently seen more in 
female population, with the female-to-male ratio of 4 to 5:1. They are 
generally seen in all age groups, although most of the patients present 
during the fifth and sixth decades of life. 
Follicular carcinoma is the second most common type of thyroid 
cancer following papillary carcinoma. The absolute incidence of 
follicular carcinoma has not changed significantly during the last several 
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decades. According to Survival, Epidemiology, and End Results (SEER) 
registry, the annual incidence in the United States from 1973 to 2003 
was about 0.8 per 100,000 persons per annum (12).Females are more 
commonly affected than males, with a slightly higher female 
predominance among conventional type carcinomas (2.5:1) than among 
oncocytic carcinomas (1.7:1) (13).These tumours are rare in paediatric age 
group. Their incidence increases with age which reaches a peak in the 5th 
decade of life. 
The data collected over the past 20 to 30 years indicate that 
follicular carcinoma, when including both the conventional type and 
oncocytic variant, makes up to approximately 15% of all thyroid cancer 
cases (66).Recently this trend is decreasing to approximately 10%.  There 
are several likely reasons that are responsible for this trend. First, the 
incidence of occurrence of thyroid papillary cancer has been increasing in 
many countries around the world; it has almost tripled in the United 
States over the last 30 years, making the incidence of follicular 
carcinoma proportionally lesser (15).Secondly an increased incidence of 
follicular carcinoma was associated with dietary iodine deficiency. 
Severe iodine deficiency has been largely eliminated or diminished by 
widespread iodization of salt and other food supplies.  
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Etiopathogenesis 
The vast majority of follicular adenomas are sporadic but some 
may even arise as manifestations of known inherited syndromes. The risk 
factors commonly implicated in the development of sporadic adenomas 
are exposure to radiations and iodine deficiency. 
External Radiation is considered as the single most important 
environmental factor associated with increased risk of developing thyroid 
carcinoma. Japanese atomic bomb survivors and in individuals who were 
living in the vicinity of nuclear accident sites had greater incidence of 
thyroid neoplasm. X-ray or γ-radiation exposure during childhood and 
adolescence is found to increase the risk of follicular adenomas as much 
as, up to 15 fold (16). The risk is mostly dose-dependent and exists even 
after a dose as small as 0.25 Gy. Most follicular adenomas develop about 
10 to 15 years of duration following exposure, but elevated risk prevails 
for at least 50 years after exposure. Follicular neoplasms that develop 
following a radiation exposure are generally solitary nodules and they 
exhibit conventional histology, although oncocytic follicular adenomas 
may also be found (17). 
Iodine deficiency is one of the important risk factor that 
contributes to the higher incidence of benign thyroid nodules. Palpable 
thyroid nodules are about 2 to 3 times more common in areas of low 
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iodine consumption when compared with areas with sufficient iodine and 
a significant proportion of those are adenomas (18). To support this 
findings, follicular adenomas can be induced in experimental animals in 
labs, by the administration of low iodine diet or drugs which interfere 
with iodine uptake and metabolism in thyroid cells (19). 
The exact process of how iodine deficiency induces adenoma 
formation is not clear as of now, but it may probably involve an increase 
in thyroid stimulating hormone (TSH) levels which stimulates the 
proliferation of thyroid cells (20). 
A cholesterol lowering agent, HMG-CoA reductase inhibitor 
simvastatin is also known to increase incidence of thyroid adenomas in 
female rats (21). This is most likely due to enhanced liver clearance of 
thyroid hormone, which might be the reason to cause elevation in TSH 
levels.  
Follicular neoplasms have been reported to develop in patients 
affected with inherited diseases like Cowden disease and Carney 
complex. Cowden disease also known as multiple hamartoma syndrome, 
is caused due to germ line mutation of the PTEN tumour suppressor gene 
which is located on chromosome 10q23.PTEN which codes for a dual 
specificity phosphatase, that functions as a negative regulator of the 
PI3K/AKT signalling pathway which is responsible for cell survival and 
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proliferation .The inherited mutations result in the loss of PTEN function 
and the chronic stimulation of AKT and its downstream targets. 
Follicular adenomas in the affected patients develop at a young age 
which are almost always multiple and bilateral. They are found to have 
conventional type of follicular adenoma appearance, occasionally clear 
cell adenomas, adenolipoma and oncocytic adenomas have also been 
reported (22). 
Molecular Genetics       
Clonality 
Follicular adenomas are true neoplasms and hence are seen to have 
a monoclonal origin i.e., arise from a single cell. This is in contrast to non 
neoplastic lesions, which have a polyclonal origin.  The clonality of a 
lesion can be determined in female tissue based on the randomness of 
inactivation of the two X chromosomes. This can be achieved by 
polymerase chain reaction-based HUMARA assay. Most of the studies 
have confirmed that follicular adenomas, which are diagnosed based on 
common morphologic criteria are generally monoclonal, that are 
consistent with their neoplastic nature (23). 
Cytogenetic alterations are  generally found in  about less than half 
of follicular adenomas and  they are  most frequently as trisomy 7 or 
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translocations involving the long arm of chromosome 19 (19q13)(24). 
Other molecular alterations involved are point mutations of the RAS 
genes, most frequently involving N-RAS codon 61, that are found in 
approximately 30% of adenomas(25). Besides studies have found that they 
are not very  specific for adenomas and  they can also occur in follicular 
carcinomas and papillary thyroid carcinomas of thyroid.PAX8-PPARγ 
rearrangement have  been found in  about as many as 8% of adenomas, 
although it has been reported much more common in thyroid follicular 
carcinomas, and hence the identification of PAX8-PPARγ rearrangement 
in a follicular tumour should prompt search for vascular or capsular 
invasion. Hyperfunctioning adenomas usually show point mutations in 
the TSH receptor gene and sometimes mutations in the Gsα (GSP) gene 
(26). 
 Hurthle cell neoplasms usually shows commonly large deletions of 
mitochondrial DNA (mtDNA), mutations of mtDNA genes  that code for 
oxidative phosphorylation (OXPHOS) proteins, and mutations of nuclear 
genes codes  also for mitochondrial OXPHOS proteins. These alterations 
are generally thought to lead to energy production defects and they lead 
to an increased proliferation of mitochondria as a compensatory 
mechanism (27). Some of the cases show mutation in the GRIM-19 gene 
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(28).PAX-8/PPARγ gene rearrangement is also found in 27% of cases of 
Hurthle cell carcinoma (29). Surprisingly RET/PTC rearrangements which 
is a hallmark of papillary thyroid carcinoma, is also found in about one 
third of Hurthle cell neoplasms. 
Follicular Neoplasm 
Follicular adenoma and carcinoma are respectively benign and 
malignant epithelial tumours of the thyroid showing follicular cell 
differentiation and lacking the diagnostic features of papillary carcinoma 
(30). Even though the neoplastic nature of follicular carcinoma is 
indisputable, the nature of follicular adenoma is more controversial (31). 
 Histochemical and molecular studies provide strong evidence 
regarding follicular adenoma diagnosed using strict morphologic criteria, 
in particular the presence of a well-defined fibrous capsule. They are 
indeed clonal lesions which supports that the lesions represent neoplasm 
rather than hyperplastic nodules (32). 
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Follicular Adenoma 
Follicular adenomas are benign, encapsulated tumours which show 
evidence of follicular cell differentiation. Molecular studies have proven 
that most adenomas have a clonal origin (33). 
Follicular adenomas are seen mostly in adults of age between 20 to 
50 years, but no age is exempt. It is more common in female (M/F ratio 1: 
6). Most of the patients presents with a solitary thyroid nodule noticed for 
variable periods. The adenomas usually lack uptake on iodine scans 
(“cold” nodules), but rare ones may be “hot” and can cause 
hyperthyroidism, which are so-called toxic adenoma. They are totally 
benign and can be adequately treated by lobectomy. 
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Clinical Features and Imaging 
Thyroid adenomas typically presents as a painless thyroid nodule 
that are incidentally discovered by palpation or during thyroid ultrasound 
carried out for any other reasons.  
Most of the adenomas are generally asymptomatic, even though 
tumours of large size cause difficulty in swallowing and other local 
symptoms. They generally grow very slowly, and some patients seek 
medical attention many years after discovering the nodule. Sometimes, 
bleeding into the tumour may occur and cause sudden pain, tenderness, 
and increase in nodule size, which may occur spontaneously or after 
procedures like vigorous neck palpation or FNAC. 
On palpation, adenomas are generally felt as a discrete mass which 
are not fixed to the neck and shows movement with the thyroid. Most of 
the patients are euthyroid. On ultrasound examination, follicular adenoma 
are seen typically as a solid, homogeneous mass that may be hyperechoic, 
isoechoic, or hypoechoic when compared to the surrounding thyroid 
tissue .The margins of the nodule appear well-defined and smooth. A 
peripheral hypoechoic halo which is a fibrous capsule may be seen. Blood 
flow can be seen by use of a colour Doppler ultrasound, low blood flow is 
more suggestive of a benign nodule, even though no ultrasound features 
allow for a reliable diagnosis of adenoma. By radionuclide scan, 
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adenomas typically appear as “cold” nodules because they concentrate 
radioiodine or other tracers less avidly than adjacent thyroid parenchyma 
.Small subset of adenomas are hyper functional and presents with 
variably prominent symptoms of hyperthyroidism. Overt thyrotoxicosis, 
are generally very rare, and most of the patients reveal subclinical 
hyperthyroidism (i.e., normal thyroid hormone levels and decreased 
serum TSH level). TSH suppression in these patients is as a result of the 
negative feedback regulation of TSH secretion due to excess thyroid 
hormone production by the nodule. Hyper functioning adenomas appear 
as “hot nodule” on imaging when compared with the adjacent thyroid 
tissue that is hypofunctional due to deprivation of TSH stimulation. 
Macroscopic and Microscopic Appearances 
Follicular adenoma and minimally invasive follicular carcinoma 
are encapsulated which are usually in distinguishable macroscopically, 
except for the capsule tends to be thicker in follicular carcinoma. Their 
size ranges from less than 1 cm to over 10 cm. they are solid, fleshy, and 
tan to light brown, sometimes having glistening quality, degeneration 
might be present. The widely invasive follicular carcinomas might lack a 
discrete capsule and show, in addition, obvious invasion beyond the main 
tumour bulk, and tumour thrombi may also be seen distending the blood 
vessels.  
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 Secondary changes like haemorrhage, hemosiderin deposition, 
sclerosis, calcification, necrosis, and cystic change are usually very 
common. Rarely, amyloid may also be present (34). Usually, the pattern of 
follicular growth is uniform within the adenoma, which is in contrast to 
hyperplastic nodules, which commonly exhibit variations in the sizes and 
shapes of individual follicles. 
Adenomas are sub classified according to the predominant pattern 
of follicular growth. The embryonal (trabecular or solid) adenoma is 
made of nests of follicular cells with few or no follicles. Micro follicular 
(fetal) adenomas are composed of small follicles which contains scanty 
luminal colloid. Simple (normofollicular) adenomas are composed of 
follicles more or less of the same size as those in the adjacent normal 
thyroid, whereas macrofollicular adenomas are composed of follicles 
which are substantially larger than those seen in adjacent normal follicles. 
Foci of clear cell change may be seen throughout the tumour or it 
can be restricted to small groups of follicles. The factors responsible for 
clear cell change in follicular adenomas are the presence of cytoplasmic 
vesicles that may originate from degenerated and cystically dilated 
mitochondria, or from dilatation of the endoplasmic reticulum or golgi 
vesicles. In certain cases clear cell change were traced to the intracellular 
accumulation of glycogen, lipid, or thyroglobulin. Some of the adenomas 
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may occasionally have cells with a signet-ring appearance. The 
cytoplasmic vacuoles are typically positive for thyroglobulin and also 
contain mucin. Hence such tumours have been referred to as signet-ring 
adenomas (35).The differential diagnosis of adenomas includes 
adenomatous (hyperplastic) nodules, follicular carcinoma, the follicular 
variant of papillary carcinoma and the follicular (tubular) variant of 
medullary carcinoma. 
Most of the adenomatous nodules are multiple and exhibit 
considerable variation in the size of the component follicles, whereas the 
follicular structure of adenomas are seen to be more uniform in 
morphology. The surrounding capsule of adenomas is complete, whereas 
it is often incomplete around adenomatous nodules. The distinction of 
follicular adenoma from carcinoma depends on the demonstration of 
capsular or vascular invasion, or both. 
Differentiating between true capsular invasion and the changes 
associated with fine-needle aspiration biopsy may be exceedingly 
difficult. These changes are referred to as WHAFFT (worrisome 
histologic alterations following fine needle aspiration of the thyroid) (36). 
Acute changes (the changes that occur less than 3 weeks after aspiration) 
include haemorrhage and granulation tissue with hemosiderin-laden 
macrophages, capsular distortion, and sometimes, infarction may also be 
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seen .Typically the foci of haemorrhage and granulation tissue are linear 
and are perpendicular to the centre of the nodule. Chronic changes , that 
occur about1 to 6 months after aspiration includes linear fibrosis adjacent 
to hemosiderin-laden macrophages; oncocytic cells, squamous 
metaplasias and spindle cells ; pseudoinvasion of the capsule; and 
calcification. Foci of pseudoinvasion tend to be linear, and the presence 
of haemorrhage, hemosiderin deposition, granulation tissue, and the focal 
and geographic pattern of the lesions indicates a fine-needle aspiration 
biopsy–induced change rather than true capsular invasion. 
The follicular variant of papillary carcinoma is characterized by a 
series of nuclear changes, which will be discussed later. The follicular 
(tubular) variant of medullary carcinoma is characterized by presence of 
chromogranin or calcitonin within the tumour cells, whereas staining for 
thyroglobulin is negative. 
Adenoma variants 
Oncocytic (Hurthle Cell) adenomas 
Oncocytic cells seen in the thyroid have been known by different 
names including Hurthle, Askanazy, and oxyphilic cells. At present the 
term “oncocytic” is recommended to describe these cells and tumours 
(80).Oncocytic adenomas are benign tumours composed predominantly of 
oncocytic cells more than 75%. Oncocytic adenoma is a common 
microscopic type of thyroid follicular adenomas. Approximately 10% to 
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15% of all adenomas belong to this variant. The tumours are usually 
round to ovoid shaped which are separated from the adjacent thyroid 
parenchyma by a fibrous capsule. In larger tumours with foci of 
degenerative changes, groups of oncocytes might become entrapped 
within the capsule. In such cases the foci should be differentiated from 
the areas of true capsular invasion to differentiate it from oncocytic 
carcinoma. On cross section, the tumours appear dark brown in colour 
and are solid in consistency. Oncocytic tumours might also undergo 
FNAC –induced or spontaneous infarct-like necrosis (37).The pattern of 
growth is usually follicular but occasionally may be also solid or 
trabecular in rare circumstances .The intra follicular colloid may be 
weakly basophilic and may also contain psammoma body–like 
calcifications .The nuclei are generally large and vesicular with coarsely 
clumped chromatin and prominent nucleoli, where in the cytoplasm is 
deeply eosinophilic and granular. The granular appearance of the 
cytoplasm is because of the presence of numerous mitochondria. Marked 
swelling of the mitochondria may lead to a clear appearance of the 
tumours cells. 
Hyperfunctioning adenoma 
Hyperfunctioning adenomas contribute to about 1% of all follicular 
adenomas approximately (38). They are generally associated with variably 
prominent symptoms of hyperthyroidism caused due to excessive thyroid 
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hormone production by the tumour cells. The nodules appear “hot” on 
radionuclide scans.  Most of the tumours carry an activation mutation of 
the TSHR or Gsα genes, leading to chronic upregulation of the cAMP 
signalling pathway that mimics constant TSH stimulation. 
Microscopically they mostly show normofollicular or 
microfollicular architecture .The follicles are shaped irregularly and 
frequently show significant variation in size and shape. They are lined by 
tall columnar or cuboidal epithelial cells. Delicate papillary projections 
into the lumen are also seen. The cells contain abundant pale 
eosinophillic and frequently vacuolated cytoplasm and uniform, basally 
located nuclei. The colloid appears usually bubbly, pale, and watery, 
often showing peripheral scalloping. Examination of thyroid parenchyma 
surrounding the adenoma typically shows evidence of suppressed TSH 
stimulation (i.e., large follicles with dense colloid lined by flattened 
epithelium). 
Adenolipoma and adenochondroma 
Adenolipoma are follicular adenomas which are composed of 
follicular elements are separated by mature fat cells. The stromal fat most 
probably arises as a sequel of metaplasia of connective tissue elements 
(39).Similar changes may be also seen in normal and hyperplastic thyroid 
nodule and in papillary carcinoma thyroid (40). The stromal components of 
25 
 
adenomas may undergo cartilaginous metaplasia (adenochondroma) very 
rarely (41). 
Follicular adenomas with papillary hyperplasia 
Follicular adenomas may sometimes also exhibit foci of papillary 
hyperplasia. These changes in the tumours are more common during the 
second and third decade of life. Some patients yield a history of exposure 
to ionizing radiation (42).The papillary processes are typically short and 
they point toward the lumina of cystically dilated follicles. 
The follicular cells seen are tall with basally situated, round nuclei. 
The central regions generally appear cystic. Alternatively, these lesions 
were referred to as hyperplastic papillary adenomas (43). Even though this 
term has resemblance to papillary carcinoma and its use should be 
avoided. Some of the hyperfunctioning (toxic) adenomas may show 
papillary hyperplasia. The follicles and papillary projections in these 
tumours are lined with tall epithelial cells. Clinical symptoms of 
hyperthyroidism are evident. 
Adenomas with bizarre nuclei 
Follicular adenomas may contain groups of cells with markedly 
enlarged and hyperchromatic nuclei, like other benign endocrine tumours. 
Thyroid tumours with these types of features have been termed adenomas 
with bizarre nuclei (44). Although the presence of such nuclei suggests a 
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possibility mostly of malignancy, they occur, in fact, more often in 
benign lesions than in malignant follicular lesions of the thyroid. This 
type of nuclear atypia is more commonly seen in hyperfunctioning 
adenomas, after radiation exposure, and in tumours that are composed of 
oncocytic cells. 
Atypical adenoma 
The term atypical adenoma has been generally used for those type 
of follicular adenomas which display atypical features but they do not 
reveal any definitive capsular or vascular invasion (45).This term was 
introduced by Hazard and Kenyon to describe adenomas which contained 
follicles that lack a central lumen with solid columns of cells, sheet like 
masses of cells, or areas of spindle cell growth (spindle cell metaplasia). 
As a result of their broad histopathologic definition of atypical adenoma, 
many pathologists have used this term indiscriminately for any adenoma 
with features that deviate from usual or typical adenomas (46).This 
approach are generally discouraged, and, in fact, Rosai and colleagues 
suggest that the term atypical adenoma be replaced with the designation 
hypercellular adenoma (47).In any event, lesions with any atypical features 
should be carefully examined  to rule out evidence of capsular or  
vascular invasion. 
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Follicular adenoma with signet-ring cells 
Follicular adenoma with signet-ring Cells is one of a rare variant of 
adenomas that is characterized by cells with large intra cytoplasmic 
vacuoles which displace and compress the nucleus to the side. In the 
H&E-stained sections, these vacuoles appear pale eosinophillic or clear  
with homogeneous or finely granular texture .The vacuoles generally 
reveal strong immune reactivity for thyroglobulin and positive staining 
for PAS after diastase digestion, whereas negative for  other mucin stains, 
such as mucicarmine and alcian blue at pH 2.5 (48). This pattern of 
staining of vacuoles is consistent with the presence of protein-
polysaccharide complexes that are derived from partial degradation of 
thyroglobulin (49). These types of adenomas are generally mistaken for 
metastatic carcinoma of signet-ring type from breast or stomach. 
Immunostaining for thyroglobulin and TTF-1 is useful in differentiating 
them. 
Follicular adenoma with clear cells 
This type of adenoma is also an uncommon variant which is 
predominantly composed of cells with clear cytoplasm due to the 
accumulation of glycogen, thyroglobulin, lipid or distended mitochondria.  
Their cytoplasm appears abundant watery clear or has a pale 
eosinophilic hue or fine granularity .The nuclei are placed centrally and 
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have smooth contours. The tumour is composed entirely of clear cells or 
may contain small clusters of cells showing typical follicular cell 
cytoplasm. 
The cells of this tumour retain thyroglobulin immunoreactivity, but 
it is typically focal and weak. In certain cases, they are PAS positive and 
diastase sensitive, which is due to their glycogen content.  
On the ultrastructural level, the cells show multiple cytoplasmic 
vacuoles. In certain cases, the vacuoles reveal the presence of residual 
cristae, suggestive of massively dilated mitochondria (50). This suggests 
that at least some of the clear-cell tumours might evolve from oncocytic 
adenomas as a result of progressive enlargement and conversion of 
mitochondria into vesicles. Follicular adenomas with this unusual 
appearance should be differentiated from follicular, papillary, and 
medullary carcinomas with clear cells, metastatic renal cell carcinoma, 
and parathyroid tissue.  
Differentiation of these lesions from follicular carcinoma follows 
the usual invasive criteria. Thyroglobulin and TTF-1 immunoreactivity is 
also useful in distinguishing this tumour from parathyroid tissue or renal 
cell carcinoma.  
Other variants of follicular adenoma 
Black adenomas of  thyroid gland  have been reported in patients 
treated with minocycline (51).These tumours have black discoloration on 
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gross examination with the cells showing abundant black pigment with 
appearance and staining qualities. 
Follicular carcinoma 
Definition 
Follicular carcinoma is a malignant well-differentiated tumour of 
the thyroid follicular cells which lacks the diagnostic nuclear features of 
papillary carcinoma.  
Incidence and Epidemiology 
Follicular carcinoma is regarded as the second most common type 
of thyroid cancer following papillary carcinoma. The data collected over 
the past 20 to 30 years show that follicular carcinoma, when combining 
both the conventional type and oncocytic variant, accounts for about 15% 
of all thyroid cancer cases (52).Follicular carcinoma affects patients with a 
higher mean age compared with follicular adenoma. Most of these 
patients present with a thyroid mass and up to 11% of patients present 
initially with distant metastasis, such as bone fracture, pain, or a pulsatile 
mass in soft tissue (53).This is in contrast to papillary carcinoma, which 
spreads by hematogenous to mostly bone and lung rather than by 
lymphatic spread (54). The likelihood of metastasis and prognosis depends 
mostly on the extent of local disease, that is, minimally invasive versus 
widely invasive type. In some cases, the follicular neoplasm shows no 
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vascular invasion and only equivocal capsular invasion. Initially follicular 
carcinoma used to comprise up to 10% to 20% of all primary thyroid 
cancers but its frequency has considerably reduced to less than 5% to 
10% in recent years (55). This drop in incidence is attributable to increased 
detection of early papillary carcinoma and adoption of a liberal approach 
in diagnosis of follicular variant of papillary carcinoma (56).Incidence of 
follicular carcinoma is greater in areas of endemic goiter,for which the 
iodine deficiency appears to be the main contributing factor,due to 
addition of iodine supplement to the diet ,the incidence of follicular 
carcinoma has significantly reduced in these geographic areas (57).In rare 
circumstances, follicular carcinoma may  also arise in a pre-existing 
follicular adenoma(58).Irradiation and Dyshormonogenesis predispose to 
the development of follicular carcinoma (59), Few cases of follicular 
neoplasm also occur as a part of hereditary non medullary thyroid cancer 
syndrome. 
Gross Features 
Follicular carcinomas are typically seen as an encapsulated nodule 
of round or oval shape .Most of them are of 2 to 4 cm in size. The cut 
surface is solid and fleshy, and in some cases of non fixed samples the 
tumour is generally seen bulging from the confines of the capsule. The 
colour of the nodule appears as gray-white in conventional type 
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carcinomas and as brown-tan in oncocytic type of carcinomas. A thick 
fibrotic capsule frequently surrounds these tumours. A very thick capsule 
is suggestive more of malignancy. Invasion of the capsule is found rarely 
on gross examination, although it can be identified in some cases. Widely 
invasive tumours are seen to have widespread invasion through the 
capsule, and in those cases no residual capsule are found. Foci of 
infarction, hemorrage and other secondary changes, either spontaneous or 
FNA induced may be seen. Very careful inspection of the capsule is 
generally required to identify areas of invasion. The entire pericapsular 
zone are essentially required to be submitted for the microscopic 
examination unless the nodule is very large. If this is not feasible at least 
10 sections from the capsule should be processed as the chance of 
detecting invasion progressively increases when 1 to 10 blocks are 
examined (60). 
Microscopic Features 
Follicular carcinomas have a well-defined and complete capsule 
typically; its thickness ranges from 0.1 to 0.3 cm (61). This capsule 
consists of parallel layers of collagen fibers and frequently may contain 
medium calibre blood vessels. In some rare instances, carcinomas have a 
thin or incomplete capsule. Architectural patterns of follicular carcinomas 
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are mostly similar to those seen in follicular adenomas, even though the 
proportion of more cellular growth patterns is greater in carcinomas. 
 A microfollicular or trabecular/solid growth pattern is seen in about 
80% of cases and normofollicular or macrofollicular patterns with 
increased colloid content in approximately 20%. 
 A insular or nested architecture may also be seen. Even though the 
growth pattern does not have any diagnostic value per se, but it should 
alert a pathologist to search more extensively for invasion, especially if 
the lesion is found to be very cellular. And also the architectural patterns 
does not correlate with the frequency of metastases or cancer-related 
death (62).Tumours that having solid, trabecular, and insular growth 
patterns should be distinguished from  the poorly differentiated thyroid 
carcinomas, which tend to have  significantly more aggressive behaviour. 
Typically the cells are cuboidal with moderately abundant 
cytoplasm, which is light eosinophillic to amphophilic. Their nuclei are 
generally small to medium, round, with smooth contours and dark or with 
more vesicular chromatin. Small nucleoli are often seen in conventional 
type carcinomas but they are much more common in oncocytic follicular 
carcinoma. Some of the tumours have more irregular nuclei and coarse 
chromatin. Random cells having very large, hyperchromatic, and highly 
irregular nuclei may also be rarely found .This exuberant nuclear atypia 
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of single cells does not increase the chance of malignancy in thyroid 
tumours and they are also seen in follicular adenomas and hyperplastic 
nodules. 
Mitotic figures might be found, typically may range from 1 to 2 per 
10 high-power fields .Higher mitotic activity might mark the areas of 
recent FNAC or of any other secondary changes. Atypical mitoses are 
uncommon. Well-differentiated follicular carcinoma does not show any 
tumours necrosis unless seen in association with spontaneous or FNA 
induced secondary changes. If present, they suggests the emergence of 
poorly differentiated thyroid carcinoma (63).The stroma is generally scant 
and they might show some hyalinization and edema..The growth pattern, 
thickness of the capsule, or cytologic features does not differentiate 
between follicular adenoma and follicular carcinoma.  
Distinction between follicular carcinoma and follicular adenoma 
In a follicular-patterned neoplasm which lacks the cytoarchitectural 
features of papillary carcinoma, the only distinguishable feature of a 
carcinoma from an adenoma is that of the presence of unequivocal 
vascular and/or capsular invasion. The features heightening the suspicion 
of follicular carcinoma are 
1. Thick fibrous capsule 
2. High cellularity with trabecular or solid growth pattern 
34 
 
3. Diffuse nuclear atypia 
4. Readily identified mitotic figures 
Due to the excellent prognosis of minimally invasive follicular 
carcinoma the criteria for invasion has to be strictly applied to avoid an 
over diagnosis of cancer (64).In cases where the invasion remains doubtful 
even after assessment of multiple deeper levels and multiple sampled 
blocks, the case should be best labelled as follicular adenoma because the 
risk of metastasis is nearly close to zero. An alternative suggestion has 
also been given to label these cases as follicular neoplasm of 
indeterminate malignant behaviour, with suggestion to treat them as 
follicular adenoma (65). 
The literature appears somewhat confusing in that some studies 
have showed development of distant metastasis in certain patients with 
equivocal or definite capsular invasion alone; this raises the issue that 
follicular carcinomas with capsular invasion only may not be that 
innocuous (66). However, these patients actually already had metastases at 
the time of diagnosis, a feature well-known to be associated with a poor 
prognosis. (67) 
Vascular invasion 
In order to qualify for the criteria of vascular invasion, the involved 
blood vessels must be located within or outside of the fibrous capsule and 
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the intravascular polypoid tumours growth should be covered with 
endothelium (68).The only situation where the requirement for 
endothelialization of the tumours island may be relaxed is when the 
intravascular tumours cluster is attached to the wall and is associated with 
thrombus formation.  
Mete and Asa have recently redefined vascular invasion as 
“tumours cells that invade through a vessel wall and endothelium, and  
those which are associated with thrombus adherent to intravascular 
tumour,”(69).But such criteria  as such generally too strict to be used in 
diagnosis of follicular carcinoma. The collections of follicles bulging 
slightly into the thin walled capsular vessels may be disregarded if deeper 
cuts and further sampling fail to reveal more convincing vascular 
invasion. Retraction artifacts around tumours islands when present can 
also simulate the appearance of a vascular invasion, but no endothelial 
lining is found in the space. Sometimes irregular clusters of 
nonendothelialized tumours with ragged borders which are not 
conforming to the contour of blood vessels may be seen inside the 
capsular vessels; they result from artifactual dislodgment of the tumours 
during sectioning of the specimen and they should not be counted as 
vascular invasion. 
A rare occurrence which might simulate vascular invasion is when 
intravascular endothelial hyperplasia that occurs in capsular blood 
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vessels.  In such cases careful scrutiny will reveal that the intravascular 
polypoid plug is formed by plump pericytes and spindle endothelial cells, 
which are quite different from neoplastic follicular epithelial cells, even 
though intravascular endothelial hyperplasia per se does not constitute 
vascular invasion, this finding  should warrants more careful sampling 
and examination to look for genuine vascular invasion if any. 
Capsular invasion 
 To fulfil the criteria for capsular invasion, complete transgression 
of the fibrous capsule should be seen. The tumour bud should extend 
beyond an imaginary line which is drawn passing through the external 
contour of the capsule (70).Tumours showing the features short of 
complete capsular transgression even after extensive sampling and after 
careful assessment should not be given a label of carcinoma, Even though 
some authors accept incomplete capsular invasion as being sufficient for 
the diagnosis of follicular carcinoma (71, 72). 
One of the major differential diagnosis is capsular rupture caused 
because of prior fine-needle aspiration. Capsular invasion and vascular 
invasion are in fact closely related phenomena. Tumours showing 
vascular invasion also frequently show capsular invasion. A tumour bud 
generally invades into or through the capsule to extend directly into a 
vascular space. 
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They are further divided into three groups based on their risk of 
metastasis 
1. Tumors “having capsular invasion only” these tumors have 
practically zero risk of metastasis (73). 
2. Tumors “with invasion of lesser than four blood vessels “they have 
a low rate of metastasis of approximately 5 %( 74). 
3. Tumors “having invasion of four or more blood vessels “they 
generally have a higher risk of metastasis.  
The collective event rate is approximately 18 %(75). In view of the 
excellent prognosis of low risk group, total lobectomy with or 
without suppressive thyroxine therapy is adequate treatment for 
low-risk patients (76). Total thyroidectomy and a radioactive iodine 
therapy should be considered for high-risk patients. 
Categories of follicular carcinoma 
After the diagnosis of follicular carcinoma has been made, it is also 
important to categorize it further into the following categorise. 
Minimally invasive follicular carcinomas.  
They are grossly encapsulated tumourswhich shows focal capsular 
or vascular invasion which is usually apparently visible only on 
histological examination. 
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Widely invasive follicular carcinomas 
 These are tumours that show widespread infiltration of the thyroid 
parenchyma and blood vessels and they generally lack complete 
encapsulation. 
At least some proportion of cases with “widely invasive follicular 
carcinomas” reported in the literature actually represents poorly 
differentiated thyroid carcinomas. At presentation, regional lymph node 
metastasis and distant metastasis are already found in 7% and 29% to 
66% of these cases, respectively (77). 
On follow-up, most of the patients are found to have further lymph 
node and distant metastases, especially to the bones and lungs (78). 
According to one long-term follow-up study conducted, 29% of 
patients died of disease, 41% remained alive with disease, and only 22% 
were alive without disease. Extension of the tumour into the soft tissues 
of the neck generally has an unfavourable influence on survival of the 
patient. This has an event rate 53% at 6 years, compared with 28% for 
carcinomas confined to the thyroid gland (79). Widely invasive carcinomas 
are very aggressive neoplasms and should to be treated by total 
thyroidectomy, radioactive iodine, and suppressive thyroxine. 
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Papillary carcinomas –follicular variant 
This is a common variant of papillary carcinoma which comprises 
15% to 20% (80) .Their diagnostic criteria includes: 
 (i) Complete absence of a well formed papillae 
(ii) Exclusively a follicular growth pattern, and  
(iii) Presence of characteristic nuclear features of papillary carcinoma. 
 A solid, nested, or trabecular architecture can be present as well as 
scattered, poorly formed papillae, but a follicular pattern should be the 
predominant pattern (>50%) in a tumour that lack a well-developed 
papillae. 
Historically, all thyroid tumours showing follicular growth were 
diagnosed as follicular carcinomas. The term follicular variant of 
papillary carcinoma was originally described by Lindsay(81).In 1960 and 
they are further characterized as a distinct variant by Chen and Rosai,who 
realized that, despite the follicular architecture, tumour showing nuclear 
features of papillary carcinoma have biologic properties of papillary 
carcinoma  rather than that of  follicular carcinoma (82).Even though they 
are designated as papillary carcinomas, they represent a distinct variant of 
papillary carcinoma with a number of characteristic molecular and 
biological features, some of which are closer to follicular tumours.  
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Follicular variant papillary carcinomas generally harbour RAS 
mutations, which are common with follicular tumours and are seen rarely 
in classic papillary carcinoma(83). They generally reveal a higher 
frequency of aneuploidy and they exhibit patterns of chromosome gains 
and losses resembling those of the follicular tumours and show gene 
expression profiles that are distinct from the classic papillary 
carcinomas(84,85). 
Investigation and Diagnosis 
Follicular carcinomas present as a solitary thyroid nodule which is 
a slowly growing, and painless. Patients might be asymptomatic or have 
dysphagia, stridor, and hoarseness. In rare cases, the presenting 
symptoms are   bone pain or pathologic bone fracture due to distant 
metastases. 
On physical examination, the nodule moves along with 
swallowing. Nodules fixed to surrounding tissues give a strong suspicion 
for invasive malignancy. Thyroid function tests are usually normal. 
Radionuclide scans typically reveal a “cold” nodule as follicular 
carcinomas concentrate radioiodine and other tracers less likely than 
adjacent thyroid parenchyma. On ultrasound examination, tumours show 
a solid hypoechoic nodule with a peripheral halo, the   halo representing 
the fibrous capsule. The outlines of the nodule are smooth and well-
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defined, unless the tumour is widely invasive. Ultrasound features 
generally cannot differentiate follicular carcinomas from adenomas.  But 
the picture of irregular, poorly defined margins, a irregular thick capsule, 
and chaotic intra nodular blood flow on colour Doppler imaging are 
features  that are more of carcinoma. A routine chest radiograph shall 
reveal tracheal deviation and pulmonary metastases. Computed 
tomography (CT) and magnetic resonance imaging (MRI) can be also 
used when invasion is suspected to better evaluate the extension of 
tumour into the adjacent neck structures. Fine-needle aspiration cytology 
(FNAC) is routinely performed for solitary thyroid nodules. Because 
FNAC cytology typically reveals a cellular aspirate suspicious for a 
follicular neoplasm, then patients are referred for surgery. 
Immunohistochemistry in Diagnosis of Follicular Neoplasms 
Immunohistochemistry is generally not required except in case of 
rare tumours showing unusual morphologic features such as prominent 
fibrovascular septa, signet ring cells, clear cells, or follicular nature of the 
neoplasm. Various antibodies have been studied for their potential value 
for the distinction between follicular carcinoma and adenoma in practice, 
but none so far has-been shown to be foolproof (86). 
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1. Immunostaining for endothelial markers has been attempted for 
finding the vascular invasion, but the results were of low success 
(87). 
2. Various other tumour markers like carcinoembryonicantigen 
(CEA), oncogene products (RAS p21,CMYC), epidermal growth 
factor cyclin-dependent Kinase inhibitor ,proliferation marker like 
Ki-67,P-glycoprotein, and high mobility group IHMGI(Y) protein 
have not been much helpful.(88) 
3. Although some antibodies such as tissue polypeptide antigen, Leu-
7, dipeptidyl aminopeptidase IV, cyclooxygenase-2, thyroid 
peroxidase (MoAb 47), HBME1, galectin-3,CITED-1,matrix 
metalloproteinase-2 and matrixmetalloproteinase-7 are reported to 
show differential staining of follicular adenomas and follicular 
carcinomas(89). Their low discriminatory power precludes their 
application for routine diagnostic purposes (90).They showed 
marked differences in the reported positivity rates in the different 
studies suggesting technical factors and interpretation criteria may 
significantly affect the results. More recent studies have also  
promoted the application of a panel of antibodies instead, but no 
consensus exists on the most optimal panel.(91) 
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PSMA 
Prostate Specific Membrane Antigen (PSMA) is an integral 
membrane protein, anchored to the epithelial cells which were used to 
detect prostatic carcinomas. Wide use of [68Ga] PSMA-HBED-
ccPET/CT for prostate imaging yielded a plethora of reports with 
unexpected detection of non prostatic tumours, including primary and 
metastatic breast, renal, neuroendocrine and other malignancies. Several 
consecutive case reports described [68Ga] PSMA-positive thyroid 
tumours, including adenomas and carcinoma. A growing number of such 
reports reflect increased use of [68Ga] PSMA-HBED-ccPET/CT and also 
high incidence of thyroid neoplasm in the population (91). 
It is been widely acclaimed that the thyroid cancer today is the 
fastest growing malignancy in the developed world. Prognosis in most of 
patients is good due to high efficacy of treatment based on thyroidectomy 
followed by radioiodine (RAI) ablation of thyroid remnants. But up to 
15–20% of all thyroid cancers might lose their ability to trap RAI, 
therefore they are being hidden for RAI imaging and therapy.RAI-
refractory thyroid cancer, whether local or disseminated, needs an 
alternative imaging strategies. It is compelling that 68Ga-PSMA PET/CT 
imaging can potentially identify RAI-refractory metastases in patients 
with negative RAI scan, and serve as a potential therapeutic opening. 
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PSMA expression has not been studied systematically in thyroid cancers, 
and only limited evidence is available about absence of PSMA expression 
in benign thyroid. Tissue microarray study has found occasional and 
weak PSMA expression in less than 5% of follicular and papillary thyroid 
cancers. 
 
Treatment and prognosis 
 Since follicular adenomas cannot be reliably distinguished from 
carcinomas by imaging or FNAC, and therefore most patients are referred 
for surgery (92).A lobectomy is mostly performed in these cases. 
Occasionally, patients are treated with levothyroxine to suppress TSH and 
followed without surgery, if the nodule decreases in size. Hyper 
functioning nodules are generally associated with a very low risk of 
malignancy and are typically managed conservatively. 
The treatment of follicular carcinomas is surgery. Because the 
diagnosis is rarely established preoperatively, the initial surgical approach 
is lobectomy. If invasion is identified from intraoperative frozen sections 
from a lobectomy specimen, the surgery may be expanded to total or 
near-total thyroidectomy. However, mostly minimally invasive follicular 
carcinomas are diagnosed only during microscopic evaluation of routine 
sections. The need for second surgery to remove the remaining lobe is 
mostly debatable. Many studies have found that total thyroidectomy has 
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an overall positive effect on outcome in patients with tumours larger than 
1 to 1.5 cm and in high-risk groups; whereas other studies report that 
there is no effect of the extended surgery on survival (93, 94). Most of the 
current guidelines suggest total thyroidectomy for patients with follicular 
carcinomas. The main reason for completion thyroidectomy is to allow 
subsequent radioiodine therapy and monitoring of tumour recurrence by 
measuring serum thyroglobulin in these patients. Most patients with 
follicular carcinoma undergo postoperative treatment with 131I, which 
improves the outcome of the patient significantly (95).External beam 
radiation therapy can be reserved only for tumours that cannot be 
completely excised. On follow-up study, it has been found that tumour 
recurrence at local site or distant metastases occurs in 15% to 30% of 
cases (96).The 10-year survival rates  in U.S. patients was 83% to 85% for 
conventional follicular carcinoma and 73% to 76% for  the oncocytic 
follicular carcinoma (97).The Factors consistently found to negatively 
affect survival are older age of the patients larger tumour size more than 4 
cm, distant metastases at presentation, and extra thyroidal extension 
(98).Additional factors that might correlate with mortality and/or 
recurrence include degree of invasiveness, (i.e., minimally invasive vs. 
widely invasive carcinomas marked vascular invasion (≥4 vessels) and 
oncocytic appearance(99,100). 
  
 
 
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
The present study was a prospective study conducted in the 
Department of Pathology; Madurai Medical College during the period  
May 2016 to August 2018.Ethical clearance for the study was obtained 
from the Ethical Committee of Madurai Medical College, Madurai. A 
total sample of 113 cases of Thyroid lesions was analyzed during this 
period. 
INCLUSION CRITERIA 
1. Follicular thyroid Adenoma (FTA) 
2. Follicular thyroid carcinoma (FTC) 
3. Follicular variant of Papillary Thyroid carcinoma (FVPTC) 
EXCLUSION CRITERIA 
1. Other neoplasms of thyroid 
2. Other non neoplastic lesions of thyroid 
METHODOLOGY AND TECHNIQUES  
The study material included 113 Thyroid lesions. (Annexure VI) 
Clinical and morphological details of the cases were recorded according 
to the Proforma (Annexure III). Operated resection specimens were 
collected and fixed in 10% neutral buffered formalin for 12 hours. 
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After adequate fixation, the specimens were photographed and 
sliced in 5–10 mm intervals. The margins were best evaluated by sections 
taken perpendicular to the specimen surface closest to the deep margin of 
the tumour. Representative bits were taken from the tumour, adjacent soft 
tissue, surgical margins and lymph nodes. They were processed routinely 
and multiple 4 to 6 micron thin paraffin sections were obtained. Staining 
was done by Haematoxylin and Eosin staining technique (Annexure IV) 
HISTOMORPHOLOGICAL EVALUATION 
Stained slides were evaluated under light microscopic examination. 
Tumours were classified as benign or malignant based on cellularity, 
nuclear features, nuclear atypia and presence or absence of atypical 
mitotic figures. Tumours were categorized broadly according to their 
pattern of differentiation (Annexure VI). 
IMMUNOHISTOCHEMICAL EVALUATION 
Selected cases of follicular adenoma, follicular carcinoma and 
follicular variant of papillary carcinoma were subjected to 
immunohistochemical evaluation with PSMA. Blocks with minimal 
necrosis or haemorrhage and representative amount of tumour tissue were 
selected for IHC study. IHC was performed using monoclonal rabbit 
PSMA, according to the manufacturer’s protocol. Prostate tissue was 
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considered as positive control. Also we performed CD31 staining to 
confirm the localization of neovasculature. 
The stained sections were assessed for the extent and intensity of 
endothelial cell staining in tumour micro-vessels and scored semi-
quantitatively. 
 
STATISTICAL ANALYSIS 
Data obtained was entered into Microsoft excel spread sheet. The 
data was analyzed using ratios and percentage. All quantitative and 
qualitative data were analyzed using Fischer’s exact test. P-value less 
than 0.05 were considered significant. Observations and results were 
compared with other studies and inferences drawn. 
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OBSERVATION AND RESULTS 
 
 
Table 1: Average incidence of thyroid specimens in our institution 
(N=9823) 
Total specimens Thyroid specimens 
9823 1521 (15.48%) 
 
9823 specimens received in our institution during the study 
period were studied. Thyroid specimens were about 15.4% of the total 
specimens received. 
 
Chart 1: Average incidence of thyroid specimens in our institution 
(N=9823) 
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Table 2: Incidence of Benign and Malignant Thyroid lesion (N=1521) 
 
Variable Frequency (Percentage) 
Malignant 42(2.76%) 
Benign 1479(97.24%) 
Total 1521 
 
The most common were benign thyroid lesion which 
contributed around 97% and malignancy about 2.67% among total 1521 
specimens studied.  
 
Chart 2: Incidence of benign and malignant thyroid lesion (N=1521) 
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Table 3: Incidence of thyroid follicular neoplasm (N=1521) 
 
Variable Frequency (Percentage) 
Thyroid follicular neoplasm 113(7.43%) 
Others 1408(92.57%) 
Total 1521 
 
Among the 1521 specimens studied, among that 7.43% were 
thyroid follicular neoplasm. 
 
Chart 3: Incidence of thyroid follicular neoplasm (N=113) 
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Table 4: Incidence of malignant lesions in total follicular lesions 
(N=113) 
Variable Frequency (Percentage) 
Benign 95(84.07%) 
Malignant 18(15.92%) 
Total 113 
 
Among 113 specimens of thyroid lesions, 84% of them were 
benign and 16% were malignant. 
 
Chart 4: Incidence of malignant lesions in total follicular lesions 
(N=113) 
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Table 5: Categorisation of thyroid follicular neoplasm (N=113) 
 
Variable Frequency (Percentage) 
Follicular adenoma 95(84.07%) 
Follicular carcinoma 1(0.88%) 
Follicular variant of papillary 
carcinoma 17(15.04%) 
Total 113 
 
Among 113 thyroid lesion studied, 84% of were follicular 
adenoma, 15% were of follicular variant of papillary carcinoma and only 
0.88% were follicular carcinoma.  
 
Chart 5: Categorisation of thyroid follicular neoplasm (N=113) 
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Table 6: Gender wise distribution of follicular neoplasm (N=113) 
 
Variable Frequency (Percentage) 
Male 14 (12.39%) 
Female 99 (87.61%) 
Total 113 
 
Females contributed around 88% of total follicular neoplasm and 
males about 12%. The female male ratio was 7:1. 
 
Chart 6: Gender wise distribution of follicular neoplasm (N=113) 
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Table 7: Gender wise distribution of malignant follicular neoplasm 
(n=18) 
Variable Frequency (Percentage) 
Female 15(83.33%) 
Male 3(16.66%) 
Total 18 
 
Among 18 cases of malignant follicular neoplasm, 84% were 
females and 16% were males.  
Chart 7: Gender wise distribution of malignant follicular neoplasm 
(n=18) 
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Table 8: Age wise distribution of thyroid follicular neoplasm (N=113) 
Variable Frequency (Percentage) 
Below 19 5(4.43%) 
20 to 29 20(17.70%) 
30 to 39 40(35.40%) 
40 t0 49 28(24.77%) 
50 to 59 14(12.39%) 
60 to 69 6(5.31%) 
Total 113 
 
Among 113 cases of thyroid follicular neoplasm, 35% belonged to 
age group 30-39yrs, 25% of them were between 40-45 yrs, and 17% 
between 20-29 yrs, 12% were between 50-59 yrs. around 4.43% below 19 
yrs and 5.31% between 60-69 yrs 
Chart 8: Age wise distribution of thyroid follicular neoplasm (N=113) 
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Table 9: Age wise distribution of malignant follicular lesions (n=18) 
Variable Frequency (Percentage) 
Less than 19 1(5.56%) 
20 to 29 2(11.12%) 
30 to 39 8(44.44%) 
40 to 49 3(16.66%) 
50 to 59 2(11.11%) 
More than 60 2(11.11%) 
 
Among 18 cases of malignant follicular neoplasm, 44% belonged 
to age group 30-39yrs, 17% of them were between 40-49 yrs, and 11% 
between 20-29 yrs, 50-59 yrs and more than 60 yrs respectively. Around 
5.56% were below 19 yrs. 
Chart 9: Age wise distribution of malignant follicular lesions (n=18) 
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Table 10: Clinical presentation of Thyroid follicular neoplasm 
(N=113) 
Variable Frequency (Percentage) 
Solitary nodule 81(71.68%) 
Multiple nodule 32 (28.32%) 
 
About 71% of thyroid follicular neoplasm presented with solitary 
nodule and 28.32 % with multiple nodule. 
Chart 10: Clinical presentation of Thyroid follicular neoplasm 
(N=113) 
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Table 11: Surgical procedure done (N=113) 
 
Variable Frequency (Percentage) 
Total thyroidectomy 38(33.63%) 
Hemi total thyroidectomy 74 (65.49%) 
Near total thyroidectomy 1(0.88%) 
 
Among 113 cases of thyroid lesion, 65% of them underwent hemi-
total thyroidectomy, 33.63% of them underwent total thyroidectomy and 
0.88% near total thyroidectomy. 
 
Chart 11: Surgical procedure done (N=113) 
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Table 12: Variants of follicular Adenoma (n=95) 
 
Variable Frequency (Percentage) 
Simple /Normofollicular  81(85.27%) 
FA with papillary hyperplasia 5(5.27%) 
FA Fetal variant 3(3.15%) 
FA Hurthle cell variant 4(4.21%) 
FA colloid variant 2(2.10%) 
Total   95 
 
Among 95 cases variants of follicular adenoma, 85% of them was 
simple/normo follicular, 5.27% were FA with papillary hyperplasia, 
4.21% FA hurthle cell variant, 3.15% FA fetal variant and  2.10% FA 
colloid variant. 
Chart  12:  Variants of Follicular Adenoma (n=95) 
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Table 13 :The intensity of PSMA staining by immunohistochemistry 
in FTA, FTC and FVPC 
Intensity score 0 1+ 2+ 3+ Total 
Fischer’s 
exact test 
(df) 
p 
value 
Follicular 
Adenoma 30 4 1 1 36 
10.384 
(3) 0.013 
Follicular 
carcinoma and 
Follicular variant 
of papillary 
carcinoma 
6 4 4 0 14 
 
In the present study 83% of follicular adenoma had negative 
staining.11% of follicular adenoma had 1+ (faint reaction at high 
power).2.7 % of follicular adenoma had 2+ (moderate intesity at low 
power) and 2.7% of them had 3+ (strong intensity at low power). 
Where as the malignant lesions (FC and FVPC) had 57% of 
negative staining ,14% of them were 1+ and 28% of them had 2+ 
staining. 
Fischer exact test was used to calculate and the P values obtained  
were less than 0.05. 
This shows that the instensity of staining were signnificantly higher 
in follicular carcinoma and follicular variant of papillary carcinoma. 
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Table 14: The Extent of PSMA staining by immunohistochemistry in 
FTA, FC and FVPC 
Extent 
score Negative Minimal Moderate Diffuse Total 
Fischer’s 
exact test 
(df) 
p value 
Follicular 
Adenoma 34 1 0 1 36 
 
10.04 
(4) 
 
 
0.023 
Follicular 
carcinoma 
and 
Follicular 
variant of 
papillary 
carcinoma 
9 0 2 2 14 
 
In the present study 86 % of the follicular adenoma had negative  
staining (0 to 9% of satined endothelial cells, 5.5 %  had minimal staining 
(10 to 39% of stained endothelial cells ,1% had moderate staining (40 to 
69%  of stained endothelial cells) and 5% had diffuse staining (more than 
70% of stained endothelial cells) 
Where as for the malignant lesions (FC and FVPC) 64% showed 
negative staining and 14% had diffuse staining. 
Fischer exact test was used to calculate and the P values obtained  
were less than 0.05. 
This shows that the extent of staining were signnificantly higher in 
follicular carcinoma and follicular variant of papillary carcinoma. 
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PHOTOGRAPHS 
 
Figure 1 - Follicular adenoma – (H&E 100x) case 1581/18 
 
Figure 2- Follicular adenoma -normofollicular – (H&E 400x)                      
case 2255/18 
64 
 
 
Figure 3 – Follicular adenoma: Well encapsulated single nodule with a 
thin capsule. Case 2255/18. 
 
Figure 4 - Follicular adenoma –Hurthle cell variant (H&E 100x)                   
case 674/18 
2255/18 
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Figure 5- Hurtle cell variant of follicular adenoma (H&E 400x)                     
case 2361/16 
 
Figure 6-Follicular Adenoma with papillary hyperplasia (H&E 100x) 
case 529/17. 
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Figure 7–Follicular variant of papillary carcinoma (H&E 100X)                    
case 1835/18 
 
Figure 8 –Follicular variant of papillary carcinoma (H&E 400x)                    
case 3270/16 
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Figure 9 – Gross picture of follicular variant of papillary carcinoma. 
Case 507/17. 
 
Figure 10 – follicular carcinoma thyroid (H&E 100x) case 1018/16 
507/17 
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Figure 11- follicular carcinoma showing capsular invasion (H&E 400x) 
case 1018/16 
 
Figure 12 – Follicular variant of papillary carcinoma showing positive 
case staining for PSMA (400x).Case 1835/18. 
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Figure 13- Follicular adenoma - PSMA staining negative. Case 3411/16. 
 
 
Figure 14- Follicular carcinoma   - Positive PSMA staining.                          
Case 1018/16 
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DISCUSSION 
 
Thyroid gland lesions having follicular growth pattern includes 
Follicular thyroid adenoma (FTA), follicular thyroid carcinoma (FTC) 
and follicular variant of Papillary Thyroid Carcinoma 
(FVPTC).Diagnosing the thyroid tumour pathology preoperatively would 
reduce the cost of management of thyroid nodules by eliminating 
diagnostic thyroidectomies  which are being performed for benign thyroid 
nodules. 
Even though FNAC is a widely recognised practice and a non 
expensive technique for diagnosing the lesion, we cannot differentiate 
between follicular adenoma and carcinoma in FNAC. Even in 
histomorphology, it is sometimes problematic for pathologist to diagnose 
a solitary encapsulated nodule with follicular histological pattern. 
In this present study, out of 113 cases of thyroid follicular 
neoplasm, 95 cases were follicular adenomas, a case was follicular 
carcinoma and 17 cases were of follicular variant of papillary carcinoma. 
Thyroid follicular neoplasm showed an incidence of 7.4% which 
correlated with similar studies conducted in other institutions 
Age distribution and sex distribution of the cases were studied.  
 
71 
 
Age incidence           
Most of the cases of follicular adenoma were in the third decade. 
This correlated with the study conducted by Hiva saffer et al which also 
showed the highest incidence of follicular adenoma in the third decade of 
life (101) .The incidence of follicular carcinoma was common in fifth and 
sixth decade. In the study done by Christopher et al the highest incidence 
of follicular adenoma was in the third decade and follicular carcinoma 
was in the sixth decade of which correlated with our study (102). The 
incidence of follicular variant of papillary carcinoma was in the third 
decade of life.      
Table number 15 gives the age incidence comparative study 
Table 15  
Age Incidence Comparison Study 
 
Sl.no. Study Age incidence 
1 
 
Hiva Saffar et al 
 
 
Follicular adenoma -Third  decade 
Follicular carcinoma –fourth decade 
Follicular variant of papillary carcinoma –
fourth decade 
2. Christopher et al Follicular adenoma- Third and fourth 
decade. Follicular carcinoma – sixth 
decade 
3. Present study Follicular adenoma- 
Third decade 
Follicular carcinoma – sixth decade 
Follicular variant of papillary carcinoma – 
Third decade 
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Sex incidence 
 
In the present study the gender incidence of thyroid follicular 
neoplasm showed that female outnumbered males with the female: male 
ratio of 7:1.In study done by Phitayakorn et al showed female: male  ratio 
of 3 :1 and  in the study done by Christopher et al showed female male 
ratio was 4 to 5 :1(102). 
The tables 16 shows gender incidence comparative study 
Table 16 
Gender incidence comparative study 
 
S.no study Gender incidence 
1 Phitayakorn et al F:M = 3 :1 
2. Christopher et al (103 ) F:M =4 to 5:1 
3. Present study F:M = 7:1 
 
 
Presentation  
 
 In the present study the mode of clinical presentation was solitary 
nodule, which was about 71.6% .This correlates with the study done by 
Klonoff DC, et al which also showed the common type of clinical 
presentation as solitary nodule (104) 
Behaviour of thyroid follicular neoplasm 
 In the present study the most common of the thyroid follicular 
neoplasm was benign tumour which constituted about 84%   of the all 
lesions. The frequency of malignant lesions was 15.9%.In study done by 
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Roasi et al, the incidence of benign to malignant follicular neoplasm was 
5:1(105). 
Distribution of thyroid follicular neoplasm 
 The incidence of follicular adenoma was 6% in the present study. 
 Whereas the study done by Silverberg et al the incidence of 
follicular adenoma was 3% and another study done by Bisi et al the 
incidence was 4.3% .(106)(107) 
Table 17 
Incidence of follicular adenoma comparative study 
Sl.no Study Incidence 
1 Silverberg  et al 3% 
2 Bisi et al 4.3% 
3 Present study 6% 
 
The incidence of follicular variant of papillary carcinoma and 
follicular carcinoma was about 1%, in the present study. 
 In the study conducted by S.K.G grebe et al, the incidence of 
follicular carcinoma was 9% and in the study conducted by xio –min et al 
the incidence of papillary carcinoma was about 9% of all papillary 
carcinoma. (108)(109) 
Variant of Follicular adenoma  
 In the present study the most common variant of follicular 
adenoma was normo follicular or simple variant which constituted about 
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85% of all follicular adenoma cases followed by follicular adenoma with 
papillary hyperplasia which was about 5% and the least common variant 
was follicular adenoma colloid variant which was about 2%.which 
correlates with the study conducted by Nikofov et al. (110) 
 
PSMA IMMUNOQUANTITATION 
An attempt has been made to study the expression of PSMA in 
thyroid follicular neoplasm, its intensity of distribution and its usefulness 
in differentiating the benign from malignant lesions. 
In the present study, PSMA immunoquantitation revealed the following 
• Follicular adenoma showed a low intensity of staining of about 
16 %. 
• Malignant follicular neoplasm (follicular carcinoma and follicular 
variant of papillary carcinoma) showed a comparatively a high 
intensity of 46%. 
• Fischer’s exact test was calculated. p value derived was 0.005 
(p<0.05) and hence the correlation is strong and statistically 
significant. 
• These results are comparable with studies by Andrey Bychkov et 
al and Hiva Saffar et al where they observed  that the intensity of 
staining of PSMA were higher in follicular carcinoma and 
follicular variant of papillary carcinoma than follicular 
adenoma.(111,112) 
  
 
 
 
 
 
 
 
 
SUMMARY 
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SUMMARY 
 
In the present prospective study of 113 cases of thyroid specimens, the 
following results were obtained: 
 
• Thyroid follicular neoplasms constituted about 7.4% of all 
thyroidectomy specimens. 
• Benign tumour was more common than the malignant .Benign 
tumours constituted about 95% and malignant lesion constituted 
about 15%. 
• The age range of thyroid follicular neoplasm was between 17 to 65 
years .The most common age group involved was between 30 to 39 
years which constituted about 35%. 
• The average age of malignant thyroid follicular neoplasm was also 
between 30 to 39 years. 
• The thyroid follicular neoplasm was more common in females than 
males with female male ratio of 7:1. 
• The most common of the follicular neoplasm was follicular 
adenoma, which constituted about 84% followed by follicular 
variant of papillary carcinoma   (15%) and follicular carcinoma 
(1%). 
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• The most common variant of follicular adenoma was simple or 
normofollicular variant which constituted about 81%, followed by 
follicular adenoma with papillary hyperplasia. 
• The most common mode of clinical presentation was solitary 
nodule (71%). 
• The most common surgical procedure done was hemi total 
thyroidectomy which was about 74%. 
• PSMA immunoquantitation results revealed higher intensity of 
staining in follicular carcinoma and follicular variant of papillary 
carcinoma. 
• Fischer’s exact test was used and p value derived was 0.005 
(p<0.05) and hence the correlation is strong and statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
77 
 
CONCLUSION 
 
 
Thyroid neoplasm represents one of the most common 
malignancies of the endocrine system. They pose a significant challenge 
to the pathologist and oncologists. 
The histomorphological distinction between follicular carcinoma 
and follicular adenoma is one of a challenging task. Different diagnostic 
tools such as IHC and molecular profiling were tried to differentiate 
between benign and malignant follicular neoplasms or differentiating 
malignant tumour subtypes. 
PSMA Expression in neovasculature can be used to distinguish 
benign and malignant follicular neoplasm by assessing the intensity and 
extent of staining of endothelial cells. PSMA-targeted radionuclide 
therapy can be used in advanced I131-resistant/negative thyroid cancers. 
 
 
 
 
 
  
 
 
 
 
 
 
 
ANNEXURES 
 
 
 
 
 
 
 
 
 
ANNEXURE I 
WHO CLASSIFICATION OF THYROID TUMOURS 
(2017) 
 
TUMOURS OF THYROID GLAND 
• Follicular adenoma 
• Hyalinising Trabacular Adenoma 
• Other encapsulated follicular pattered thyroid tumours 
 Follicular adenoma of Uncertain malignant potential 
 Well differentiated Tumours of Uncertain malignant 
potentaial 
 noninvasive follicular thyroid neoplasm with papillary 
like  nuclear features 
• Papillary thyroid carcinoma 
 Papillary carcinoma 
 Follicular variant of papillary carcinoma thyroid 
 Encapsulated variant of Papillary thytroid carcinoma 
 Papillary microcarcinoma 
 Columnar cell variant of PTC 
 Oncocytic variant of PTC 
• Follicular thyroid carcinoma (FTC ) NOS 
 Follicular thyroid carcinoma , minimally invasive 
 
 
 Follicular thyroid carcinoma ,,encapsulated angioinvasive 
 Follicular thyroid ,carcinoma widely invasive 
• Hurthle (oncocytic ) cell tumours 
 Hurthle cell Adenoma 
 Hurthle cell carcinoma 
• Poorly differentiated thyroid carcinoma 
• Anaplastic thyroid carcinoma 
• Squamous cell carcinoma 
• Medullary thyroid carcinoma 
• Mixed medullary and follicular thyroid carcinoma 
• Mucoepidermoid carcinoma 
• Sclerosing mucoepidermoid  carcinomawith eosinophilia 
• Mucinous carcinoma 
• Ectopic thymoma 
• Spindle epithelial tumour with thymus like differentiation 
• Intra thyroid thymic carcinoma 
• Paraganglioma and Mesenchymal stromal tumours 
 Paraganglioma 
 Peripheral nerve sheath tumour(PNSTs) 
• Schwannoma 
• Malignant PNST 
 
 
 Benign vascular tumours 
• Hemangioma 
• Cavernous haemangioma 
• Lymphangioma 
• Angiosarcoma 
• Smooth muscle tumours 
 Leiomyoma 
 Leimyosarcoma 
 Solitary fibrous tumours 
• Hematolymphoid tumours 
 Langerhans cell Histiocytosis 
 Rosai –dorfman disease 
 Follicular dentritic cell sarcoma 
 Primary thyroid lymphoma 
• Germ cell tumours 
 Benign teratoma 
 Immature teratoma 
 Malignant teratoma 
• Secondary tumours 
 
 
 
 
ANNEXURE II 
Tumor, Node, Metastasis (TNM) Staging Scheme for 
Tumors of the Thyroid 
PRIMARY TUMOR (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor ≤2 cm greatest dimension limited to the thyroid 
T2 Tumor >2 cm but not >4 cm limited to the thyroid 
T3 Tumor >4 cm in greatest dimension limited to the thyroid or any tumor with 
minimal extrathyroid extension (e.g., extension to sternothyroid muscle or 
perithyroid soft tissues) 
T4a Tumor of any size extending beyond the thyroid capsule to invade 
subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal 
nerve 
T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal 
vessels All anaplastic carcinomas are considered T4 tumors Intrathyroidal 
anaplastic carcinoma–surgically resectable Extrathyroidal anaplastic 
carcinoma–surgically unresectable 
 
 
 
 
 
 
REGIONAL LYMPH NODES (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1a Metastasis to Level VI (pretracheal, paratracheal, and 
prelaryngeal/Delphian lymph nodes 
N1b Metastasis to unilateral, bilateral, or contralateral cervical or superior 
mediastinal lymph nodes 
 
DISTANT METASTASIS (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
STAGE GROUPING 
Separate stage groupings are recommended for papillary or follicular, medullary, 
and anaplastic carcinoma. 
Papillary or Follicular (<45 years) 
Stage I Any T Any N M0 
Stage II Any T Any N M1 
Papillary or Follicular (45 years and older) 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
 
 
Stage III T3 N0 M0 
Stage III T1 N1a M0 
Stage III T2 N1a M0 
Stage III T3 N1a M0 
Stage IVA T4a N0 M0 
Stage IVA T4a N1a M0 
Stage IVA T1 N1b M0 
Stage IVA T2 N1b M0 
Stage IVA T3 N1b M0 
Stage IVA T4a N1b M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
Medullary Carcinoma 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
Stage III T2 N1a M0 
Stage III T2 N1a M0 
Stage III T3 N1a M0 
Stage IVA T4a N0 M0 
Stage IVA T4a N1a M0 
 
 
Stage IVA T1 N1b M0 
Stage IVA T2 N1b M0 
Stage IVA T3 N1b M0 
Stage IVA T4a N1b M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
Anaplastic Carcinoma 
All anaplastic carcinomas are considered Stage IV 
Stage IVA T4a Any N M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE III 
PROFORMA 
Name:  Age / Sex: 
IP No: Unit & Ward: 
HPE No: 
H/O Presenting illness: 
Significant past history (if any): 
Type of specimen: 
Procedure done: 
Details of any relevant imaging studies: 
Details of any investigation for metastatic disease: 
 
 
 
 
 
 
 
 
 
ANNEXURE IV 
HAEMATOXYLIN AND EOSIN STAINING METHOD 
1. Sections will be deparaffinised with xylene for 20 minutes. 
2. Sections will be hydrated through descending concentrations 
(absolute alcohol,90%, 70%, 50%) of ethanol to water solutions. 
3. Sections will be rinsed in distilled water. 
4. Sections will be placed in Ehrlich haematoxylin stain for 20-30 
minutes. 
5. Sections will be rinsed with water. 
6. Differentiation will be done by immersing the sections in 1% acid 
alcohol for 10seconds. 
7. Sections will be rinsed with water. 
8. Blueing will be done by keeping the sections in Scott’s tap water 
for 2-10minutes. 
9. Counterstaining will be done with 1% aqueous Eosin for 1-3 
minutes. 
10. Sections will be rinsed with water. 
11. Sections will be dehydrated through increasing concentrations of 
ethanolsolutions (50%, 70%, 95%, absolute alcohol) and cleared 
with xylene. 
12. Sections will be mounted with DPX. 
 
 
ANNEXURE V 
KEY TO MASTER CHART 
SEX: 
M - Male 
F - Female 
HPE NO – Histopathological Examination Number 
Presentation  
SNG –solitary nodular goitre 
MNG –multinodular goitre 
Surgical procedure 
HT- hemi thyroidectomy. 
TT- total thyroidectomy. 
PSMA Intensity score 
Score 0 :no reaction 
Score 1+    : Faint reaction visible only at high power  
Score 2+    : Moderate intensity at low power 
Score 3+    : Strong reaction easily visible at low power  
 
 
 
PSMA extent score 
Percentage of stained 
endothelial cells (%) Interpretation 
0-9 Negative 
10-39 Minimal 
40-69 Moderate 
≥70 Diffuse 
 
 
 
 
 
 
 
 
 
 
ANNEXURE VI A 
MASTER CHART OF HISTOPATHOLOGY OF THYROID FOLLICULAR NEOPLASMS 
 
Sl No. HPE NO. AGE SEX PRESENTATION SURGERY DIAGNOSIS 
1 613/16 35 F SNG HT follicular adenoma with degenerative changes 
2 631/16 55 F MNG TT follicular adenoma -oncocytic variant with degenerative changes 
3 717/16 30 M SNG HT follicular adenoma with degenerative changes 
4 765/16 60 F MNG TT follicular adenoma 
5 1018/16 65 F MNG TT follicular carcinoma 
6 1066/16 48 F SNG HT follicular adenoma with degenerative changes 
7 1033/16 45 F SNG HT follicular adenoma with degenerative changes 
8 1150/16 35 F SNG HT follicular adenoma with degenerative changes 
9 1226/16 39 F SNG HT follicular adenoma 
10 1376/16 25 F MNG tt follicular adenoma with degenerative changes 
11 1382/16 52 M SNG HT follicular adenoma with degenerative changes 
12 1485/16 19 F SNG ht follicular adenoma with degenerative changes 
13 1507/16 30 F MNG TT follicular adenoma 
14 1588/16 26 F MNG TT follicular adenoma -fetal variant 
15 1722/16 36 F SNG HT follicular adenoma 
16 1769/16 30 F SNG HT follicular adenoma 
17 1827/16 32 F SNG HT follicular adenoma with degenerative changes 
18 2068/16 21 F SNG HT follicular adenoma 
19 2177/16 55 F SNG HT follicular adenoma 
 
 
20 2227/16 38 F SNG TT Follicular variant of papillary carcinoma 
21 2242/16 49 F MNG TT colloid adenoma 
22 2361/16 35 F SNG HT follicular adenoma -hurthle cell variant 
23 2409/16 25 F SNG HT follicular adenoma 
24 2416/16 26 F MNG TT follicular adenoma with degenerative changes 
25 2429/16 40 F SNG TT follicular adenoma with degenerative changes 
26 2509/16 42 F SNG NEAR TOTAL Follicular adenoma 
27 2512/16 40 F SNG HT Follicular variant of papillary carcinoma 
28 2575/16 22 F SNG HT follicular adenoma 
29 2670/16 22 F SNG HT follicular adenoma 
30 2802/16 23 F SNG HT follicular adenoma with degenerative changes 
31 2937/16 30 F SNG HT follicular adenoma 
32 2979/16 31 F SNG HT follicular adenoma 
33 2986/16 15 F SNG HT follicular adenoma 
34 3004/16 46 M MNG TT follicular adenoma 
35 3112/16 27 F MNG TT Follicular variant of papillary carcinoma 
36 3269/16 34 F SNG HT follicular adenoma 
37 3270/16 30 F MNG TT Follicular variant of papillary carcinoma 
38 3272/16 45 F MNG TT follicular adenoma 
39 3411/16 50 F SNG HT follicular adenoma 
40 3668/16 33 F SNG HT follicular adenoma 
41 3808/16 48 F SNG HT follicular adenoma 
42 25/17 37 F SNG HT follicular adenoma 
43 314/17 24 F SNG HT follicular adenoma 
 
 
44 346/17 58 M SNG TT follicular adenoma 
45 504/17 33 F MNG TT Follicular variant of papillary carcinoma 
46 522/17 66 M SNG HT follicular adenoma 
47 529/17 32 F MNG TT follicular adenoma with papillary hyperplasia 
48 550/17 55 F MNG TT Follicular variant of papillary carcinoma 
49 656/17 37 F SNG HT follicular adenoma 
50 861/17 43 f SNG HT follicular adenoma with degenerative changes 
51 955/17 60 F SNG HT follicular adenoma with degenerative changes 
52 1005/17 36 F SNG HT Follicular variant of papillary carcinoma 
53 1117/17 32 F SNG tt Follicular variant of papillary carcinoma 
54 1217/17 40 F SNG HT follicular adenoma with degenerative changes 
55 1316/17 33 F MNG TT Follicular variant of papillary carcinoma 
56 1394/17 35 F SNG HT follicular adenoma 
57 1443/17 24 F SNG HT follicular  adenoma 
58 1478/17 57 F SNG HT follicular adenoma 
59 1515/17 30 F SNG HT follicular adenoma 
60 1521/17 40 M MNG TT follicular adenoma 
61 1611/1`7 19 F MNG TT follicular adenoma with papillary hyperplasia 
62 1889/17 46 F MNG TT Follicular variant of papillary carcinoma 
63 1995/17 48 F SNG HT follicular adenoma 
64 2044/17 35 F SNG HT foillicular adenoma 
65 2089/17 28 F SNG HT foillicular adenoma 
66 2272/17 20 F SNG HT foillicular adenoma 
67 2315/17 45 F SNG TT Follicular variant of papillary carcinoma 
 
 
68 2507/17 47 F SNG HT follicular adenoma 
69 2548/17 37 F MNG TT follicular adenoma 
70 2911/17 27 M SNG HT Follicular variant of papillary carcinoma 
71 2953/17 55 M SNG HT follicular adenoma with degenerative changes 
72 3190/17 50 M MNG TT follicular adenoma- colloid variant 
73 3202/17 43 F MNG TT follicular adenoma with degenerative changes 
74 3360/17 55 M SNG HT follicular adenoma -fetal variant 
75 3539/17 36 F SNG HT follicular adenoma 
76 3682/17 35 F MNG TT follicular adenoma 
77 3708/17 33 F MNG TT Follicular variant of papillary carcinoma 
78 3801/17 60 F SNG HT follicular adenoma with degenerative changes 
79 40/18 38 F MNG TT follicular adenoma 
80 116/18 47 F MNG TT follicular adenoma 
81 431/18 30 F SNG HT follicular adenoma 
82 438/18 26 F SNG HT follicular adenoma 
83 480/18 46 F SNG HT follicular adenoma 
84 611/18 44 M MNG TT follicular adenoma with degenerative changes 
85 674/18 47 F SNG HT follicular adenoma -Hurthle cell variant 
86 759/18 23 f SNG HT Follicular adenoma 
87 899/18 30 F SNG HT Follicular adenoma 
88 1205/18 45 f MNG TT follicular adenoma with degenerative changes 
89 1207 /18 21 M SNG TT follicular adenoma -microfollicular variant 
90 1384/18 42 F SNG HT follicular adenoma with degenerative changes 
91 1405/18 35 F SNG HT Follicular adenoma 
 
 
92 1410/18 40 F SNG HT Follicular adenoma 
93 1423/18 61 M MNG TT Follicular variant of papillary carcinoma 
94 1448/18 42 F SNG HT follicular adenoma with hashimaotos thyroiditis 
95 1478/18 37 F MNG TT Follicular adenoma 
96 1581/18 55 F SNG HT Follicular adenoma 
97 1629/18 45 F SNG HT Follicular adenoma 
98 1`636/18 23 F SNG HT Follicular adenoma 
99 1784/18 29 F MNG TT Follicular adenoma 
100 1835/18 58 F SNG HT Follicular variant of papillary carcinoma 
101 2019/18 34 F SNG HT follicular adenoma 
102 2038/18 17 F MNG TT Follicular variant of papillary carcinoma 
103 2044/18 44 F SNG HT follicular adenoma 
104 2048/18 30 F SNG HT follicular adenoma with papillary hyperplasia 
105 2177/18 57 F SNG HT follicular  adenoma- microfollicular variant. 
106 2195/18 57 F SNG HT follicular adenoma with degenerative changes 
107 2255/18 37 F SNG HT follicular adenoma 
108 2321/18 21 F SNG HT follicular adenoma -colloid variant 
109 2348/18 34 F SNG HT follicular adenoma 
110 2379/18 23 f SNG HT folicular adenoma with papillary hyperplasia 
111 2418/18 47 F SNG HT follicular adenoma with papillary hyperplasia 
112 2516/18 17 F SNG HT follicular adenoma with degenerative changes 
113 2648/18 38 M SNG HT Follicular variant of papillary carcinoma 
 
 
 
ANNEXURE VI B 
IMMUNO HISTOCHEMISTRY MASTER CHART 
SL.No HPE NO. AGE SEX PRESEN TATION Surgery Diagnosis PSMA Intensity PSMA EXTENT 
1 613/16 35 F SNG HT follicular adenoma with degenerative changes 0 negative 
2 631/16 55 F MNG TT follicular adenoma -oncocytic variant with   degenerative changes 0 negative 
3 1018/16 65 F MNG TT follicular carcinoma 3 diffuse 
4 1226/16 39 F SNG HT follicular adenoma 0 negative 
5 1588/16 26 F MNG TT follicular adenoma -fetal variant 0 negative 
6 1769/16 30 F SNG HT follicular adenoma 0 negative 
7 2512/16 40 F SNG HT follicular variant of papillary carcinoma 1 moderate 
8 2575/16 22 F SNG HT follicular adenoma 0 negative 
9 2670/16 22 F SNG HT follicular adenoma 0 negative 
10 2802/16 23 F SNG HT follicular adenoma with degenerative changes 0 negative 
11 3112/16 27 F MNG TT follicular variant of papillary carcinoma 0 negative 
12 3269/16 34 F SNG HT follicular adenoma 0 moderate 
13 3411/16 50 F SNG HT follicular adenoma 0 negative 
14 504/17 33 F MNG TT follicular variant of papillary carcinoma 0 negative 
15 550/17 55 F MNG TT follicular variant of papillary carcinoma 0 negative 
16 955/17 60 F SNG HT follicular adenoma with degenerative changes 1 negative 
17 1005/17 36 F SNG HT follicular variant of papillary carcinoma 2 moderate 
18 1117/17 32 F SNG tt follicular variant of papillary carcinoma 0 negative 
19 1316/17 33 F MNG TT follicular variant of papillary carcinoma 2 moderate 
20 1611/1`7 19 F MNG TT follicular adenoma with papillary hyperplasia 0 negative 
21 1889/17 46 F MNG TT follicular variant of papillary carcinoma 0 negative 
22 1995/17 48 F SNG HT follicular adenoma 0 negative 
 
 
23 2044/17 35 F SNG HT foillicular adenoma 0 negative 
24 2089/17 28 F SNG HT foillicular adenoma 0 negative 
25 2272/17 20 F SNG HT foillicular adenoma 0 negative 
26 2315/17 45 F SNG tt follicular variant of papillary carcinoma 0 minimum 
27 2507/17 47 F SNG HT follicular adenoma 2 diffuse 
28 2548/17 37 F MNG TT follicular adenoma 0 negative 
29 2953/17 55 M SNG HT follicular adenoma with degenerative changes 0 negative 
30 3190/17 50 M MNG TT follicular adenoma- colloid variant 0 negative 
31 3360/17 55 M SNG HT follicular adenoma -fetal variant 3 Diffuse 
32 1207 /18 21 M SNG TT follicular adenoma -microfollicular variant 1 diffuse 
33 1384/18 42 F SNG HT follicular adenoma with degenerative changes 0 negative 
34 1405/18 35 F SNG HT Follicular adenoma 0 negative 
35 1410/18 40 F SNG HT Follicular adenoma 1 negative 
36 1423/18 61 M MNG TT follicular variant of papillary carcinoma 0 negative 
37 1478/18 37 F MNG TT Follicular adenoma 0 negative 
38 1581/18 55 F SNG HT Follicular adenoma 0 negative 
39 1638/18 23 F SNG HT Follicular adenoma 0 negative 
40 1835/18 58 F SNG HT follicular variant of papillary carcinoma 2 diffuse 
41 2019/18 34 F SNG HT follicular adenoma 0 negative 
42 2038/18 17 F MNG TT follicular variant of papillary carcinoma 1 negative 
43 2044/18 44 F SNG HT follicular adenoma 1 negative 
44 2177/18 57 F SNG HT follicular adenoma microfollicular variant. 0 negative 
45 2195/18 57 F SNG HT follicular adenoma with degenerative changes 0 negative 
46 2255/18 37 F SNG HT follicular adenoma 0 negative 
47 2321/18 21 F SNG HT follicular adenoma -colloid variant 3 negative 
48 2348/18 34 F SNG HT follicular adenoma 0 minimum 
49 2379/18 23 f SNG HT folicular adenoma with papillary hyperplasia 0 minimum 
50 2648/18 38 M SNG ht follicular variant of papillary carcinoma 2 diffuse 
 
 
ANNEXURE VII 
LIST OF ABBREVAITIONS USED 
 
FA   – Follcular adenoma 
FC  - follicular carcinoma 
FVPC  – follicular variant of papillary carcinoma 
CD   -  Cluster of Differentiation 
FNA   – Fine needle aspiration 
WHO  – World Health Organisation 
FFPE  -  Formalin Fixed Paraffin Embedded 
IHC   – Immunohistochemistry 
TNGM  -  Tumour Node Grade Metastasis 
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